Advertisement: KISS
Advertisement: EY mid
Advertisement: CPL mid banner
Advertisement: Wild Knight Vodka
Advertisement: Cambridge Network
RealVNC mid banner careers
ARM Innovation Hub
RealVNC mid-banner general
Advertisement: Mobas mid banner
Barr Ellison Solicitors – commercial property
TTP
2 May, 2018 - 12:36 By Kate Sweeney

Abcam alliance with Chinese diagnostics leader

Abcam, the Cambridge innovator in reagents and research tools, has joined forces with a Chinese based diagnostics company to develop novel companion diagnostic (CDx) kits.

The alliance is with Shuwen Biotech, a leading player in the development and commercialisation of CDx.

The partners will jointly leverage their respective capabilities in producing high-quality antibodies and CDx kit development and commercialisation, to better serve the needs of the global pharmaceutical industry.

The parties say they are responding to the increasing range of development needs from pharmaceutical and biopharma developers, patients, healthcare professionals and regulatory authorities.

The nature of any joint work is yet to be determined in detail but is likely to encompass Abcam providing reproducible highly-specific recombinant antibodies to key targets which Shuwen will incorporate into companion diagnostic kits.

Jay Z. Zhang, Shuwen’s CEO and chairman, said: “Shuwen has a long-standing reputation amongst pharmaceutical companies for companion diagnostic kit development and central lab testing and Abcam is a recognised leader in quality antibody development.

“This alliance will undoubtedly further strengthen Shuwen’s capabilities in developing quality companion diagnostic kits especially immunoassay kits. We have seen continuous advances at all levels in personalised medicine over the past few years and these can only continue through innovative technologies like those that will be born out of joint efforts between Shuwen and Abcam.”

Since 2011, Shuwen has established strategic partnerships with numerous outstanding academic and commercial institutions such as Yale University, the University of Chicago, the Max-Plank Institute and BioNTech, among others, in the form of exclusive licensing of over 20 first-in-class diagnostic technologies and 50+ patents.

These cover a range of novel biomarkers for companion diagnostics and other diagnostics in the fields of cancer, women’s health, critical care, plus health screening and other fields. 

Shuwen has an in-house development team, CAP-accredited central lab and IVD manufacturing facilities – all in line with global standards to deliver transformational products to customers globally and create new possibilities in the advancement of health.

John Baker (pictured), Abcam's SVP Portfolio and Business Development said:“Abcam is pleased to establish this long-term collaborative strategic partnership, combining our unique capabilities to develop sensitive, highly-specific and validated antibodies with Shuwen’s proven track-record in the CDx space. 

“Our work with Shuwen will focus on developing efficient and comprehensive solutions to advance clinical diagnostics and precision medicine, faster."

Newsletter Subscription

Stay informed of the latest news and features